Myelodysplastic Syndromes
June 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients.
Authors:Spetsieris N, Diamantopoulos P, Zervakis K, Giannakopoulou N, Rougala N, Garefalakis G, Skarlatou V, Viniou NA
Journal:Medicine (Baltimore). 2018 Apr;97(17):e0505. doi: 10.1097/MD.0000000000010505.

2:Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review.
Authors:Ma Y, Shen J, Wang LX
Institution:Department of Hematology, Navy General Hospital of PLA, Beijing, China.
Journal:Medicine (Baltimore). 2018 Apr;97(16):e0434. doi: 10.1097/MD.0000000000010434.

3:Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Authors:Wang C, Yang Y, Gao S, Chen J, Yu J, Zhang H, Li M, Zhan X, Li W
Institution:Department of Hematology, The First Hospital of Jilin University, Changchun, China. China. China. China. China. Electronic address: jdyylw@163.com.
Journal:Crit Rev Oncol Hematol. 2018 Feb;122:123-132. doi: 10.1016/j.critrevonc.2017.12.013. Epub 2018 Jan 3.

4:Iron overload in myelodysplastic syndromes (MDS).
Authors:Gattermann N
Institution:Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany. gattermann@med.uni-duesseldorf.de.
Journal:Int J Hematol. 2018 Jan;107(1):55-63. doi: 10.1007/s12185-017-2367-1. Epub 2017 Nov 25.

5:Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Authors:Schroeder T, Rautenberg C, Kruger W, Platzbecker U, Bug G, Steinmann J, Klein S, Hopfer O, Nachtkamp K, Kondakci M, Geyh S, Haas R, Germing U, Bornhauser M, Kobbe G
Institution:Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Dusseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de.; Clinic and Policlinic for Internal Medicine C, Hematology and Oncology, University of Greifswald, Greifswald, Germany.; Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Dresden, Germany.; Department of Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany.; Med. Clinic III, University Medicine Mannheim, Mannheim, Germany.
Journal:Ann Hematol. 2018 Feb;97(2):335-342. doi: 10.1007/s00277-017-3185-5. Epub 2017 Nov 18.

6:Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome.
Authors:Li H, Wang L, Wu Y, Su L, Zhao H, Zhang Y, Wang Z, Huang D, Huang Z, Wu X, Li X, Ye F, Yu F, Liu H, Wang JW, Cong J, Sun W, Chen HR, Wang J, Han B
Institution:Fu-Xing Hospital, Capital Medical College, Beijing, China.
Journal:Acta Haematol. 2017;138(3):168-174. doi: 10.1159/000479485. Epub 2017 Oct 19.

7:SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
Authors:Sallman DA, Tanaka TN, List A, Bejar R
Institution:Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Institute, Tampa, FL. Electronic address: alan.list@moffitt.org.
Journal:Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):613-620. doi: 10.1016/j.clml.2017.09.018. Epub 2017 Sep 25.

8:A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
Authors:Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M
Institution:Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Department of Hematology, Fujita Health University School of Medicine, Aichi, Japan.; Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Journal:Am J Hematol. 2017 Dec;92(12):1324-1332. doi: 10.1002/ajh.24905. Epub 2017 Sep 28.

9:Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Authors:Platzbecker U, Germing U, Gotze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A
Institution:Universitatsklinikum "Carl Gustav Carus" der Technischen Universitat Dresden, Dresden, Germany. Electronic address: uwe.platzbecker@uniklinikum-dresden.de. Dusseldorf, Dusseldorf, Germany. Germany.
Journal:Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1.

10:Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.
Authors:Modi D, Deol A, Kim S, Ayash L, Alavi A, Ventimiglia M, Bhutani D, Ratanatharathorn V, Uberti JP
Institution:Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.; Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, USA.
Journal:Bone Marrow Transplant. 2017 Nov;52(11):1530-1536. doi: 10.1038/bmt.2017.182. Epub 2017 Sep 4.

11:Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
Authors:Nazha A, Bejar R
Institution:Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA. Cancer Center, 3855 Health Sciences Drive MC 0820, La Jolla, CA, 92093-0820, USA. rabejar@ucsd.edu.
Journal:Curr Hematol Malig Rep. 2017 Oct;12(5):461-467. doi: 10.1007/s11899-017-0407-9.

12:Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
Authors:Lee JH, Kim YJ, Sohn SK, Yoon SS, Kim H, Cheong JW, Lee WS, Lee GW, Lim SN, Kim MK, Lee HS, Kim HJ
Institution:Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: jhlee3@amc.seoul.kr.; Department of Hematology, Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Hematology-Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
Journal:Leuk Res. 2017 Sep;60:135-144. doi: 10.1016/j.leukres.2017.08.004. Epub 2017 Aug 15.

13:Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
Authors:Zeidan AM, Pullarkat VA, Komrokji RS
Institution:Department of Hematology, Yale Cancer Center, New Haven, CT, United States. Electronic address: amer.zeidan@yale.edu. National Medical Center, Duarte, CA, United States. States.
Journal:Crit Rev Oncol Hematol. 2017 Sep;117:57-66. doi: 10.1016/j.critrevonc.2017.07.002. Epub 2017 Jul 12.

14:Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Authors:Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G
Institution:The University of Texas MD Anderson Cancer Center, Houston, TX.
Journal:Blood. 2017 Sep 28;130(13):1514-1522. doi: 10.1182/blood-2017-06-788497. Epub 2017 Aug 3.

15:A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
Authors:Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD
Institution:Department of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Journal:Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31.

16:Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Authors:Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras Gonzalez GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F
Institution:Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA ndaver@mdanderson.org fravandi@mdanderson.org.; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.; Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.; Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.; Sunesis Pharmaceuticals Inc., South San Francisco, CA, USA.
Journal:Haematologica. 2017 Oct;102(10):1709-1717. doi: 10.3324/haematol.2017.168732. Epub 2017 Jul 20.

17:Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Authors:Slade M, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Romee R
Institution:BMT and Leukemia Program, Washington University School of Medicine, St. Louis, Missouri. Missouri. Missouri. Missouri. Missouri. Missouri. Electronic address: rromee@wustl.edu.
Journal:Biol Blood Marrow Transplant. 2017 Oct;23(10):1736-1743. doi: 10.1016/j.bbmt.2017.06.019. Epub 2017 Jul 5.

18:Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Authors:Wang H, Huang M, Zhao Y, Qi JQ, Chen C, Tang YQ, Qiu HY, Fu CC, Tang XW, Wu DP, Ruan CG, Han Y
Institution:Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.; Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.; Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. Electronic address: ruanchanggeng@suda.edu.cn.; Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. Electronic address: hanyue@suda.edu.cn.
Journal:Biol Blood Marrow Transplant. 2017 Oct;23(10):1678-1684. doi: 10.1016/j.bbmt.2017.06.010. Epub 2017 Jun 19.

19:A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.
Authors:Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, Slama B, Badre S, Gasal E, Mehta B, Franklin J
Institution:University Hospital Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany. Medical School, Patras, Greece. Calabria, Italy. Switzerland. Leuven, Leuven, Belgium. and Faculty of Medicine, Masaryk University, Brno, Czech Republic. Avignon, France.
Journal:Leukemia. 2017 Sep;31(9):1944-1950. doi: 10.1038/leu.2017.192. Epub 2017 Jun 19.

20:Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Authors:Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J
Institution:Service d'Hematologie Clinique, Hopital St. Louis and Paris 7 University, Paris, France. Netherlands. Houston, TX, USA. USA.
Journal:Br J Haematol. 2017 Sep;178(6):906-913. doi: 10.1111/bjh.14792. Epub 2017 Jun 14.

21:Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Authors:Festuccia M, Baker K, Gooley TA, Sandmaier BM, Deeg HJ, Scott BL
Institution:Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA.; Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA; Medical Oncology, University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, WA. Electronic address: bscott@fredhutch.org.
Journal:Biol Blood Marrow Transplant. 2017 Sep;23(9):1509-1514. doi: 10.1016/j.bbmt.2017.05.034. Epub 2017 Jun 30.

22:Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.
Authors:Zhang ZH, Lian XY, Yao DM, He PF, Ma JC, Xu ZJ, Guo H, Zhang W, Lin J, Qian J
Institution:Department of Hematology, Affiliated People's Hospital of Jiangsu University, 8 Dianli Rd., Zhenjiang, 212002, Jiangsu, People's Republic of China. qianjun0007@hotmail.com.; The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People's Republic of China. linjiangmail@sina.com.; Laboratory Center, Affiliated People's Hospital of Jiangsu University, 8 Dianli Rd., Zhenjiang, 212002, Jiangsu, People's Republic of China. linjiangmail@sina.com.; The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People's Republic of China. qianjun0007@hotmail.com.
Journal:J Cancer Res Clin Oncol. 2017 Sep;143(9):1853-1864. doi: 10.1007/s00432-017-2429-z. Epub 2017 May 3.

23:Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.
Authors:Patel SS, Sekeres MA, Nazha A
Institution:a Leukemia Program, Department of Hematology and Medical Oncology , Taussig Cancer Institute, Cleveland Clinic , Cleveland , OH , USA.
Journal:Leuk Lymphoma. 2017 Nov;58(11):2532-2539. doi: 10.1080/10428194.2017.1307361. Epub 2017 Mar 28.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: July 4, 2018
185 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS13104086

Coupon Expires: August 23, 2018



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2018 Medifocus, Inc. All rights reserved.